Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

BACKGROUND: Patients with rheumatoid arthritis (RA) with an inadequate response to TNF antagonists (aTNFs) may switch to an alternative aTNF or start treatment from a different class of drugs, such as rituximab (RTX). It remains unclear in which clinical settings these therapeutic strategies offer m...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Finckh, A, Ciurea, A, Brulhart, L, Möller, B, Walker, U A, Courvoisier, D, Kyburz, D, Dudler, J, Gabay, C, Arthritis, on the behalf of the doctors of the Swiss Clinical Quality Management Programme for Rheumatoid
Format: Artigo
Jezik:Inglês
Izdano: BMJ Group 2010
Teme:
Clinical and epidemiological research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2800201/
https://ncbi.nlm.nih.gov/pubmed/19416802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ard.2008.105064
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items